gustav, Author at Double Bond Pharmaceutical

Beyond Incrementalism – Investing in the Next Blockbuster Glioblastoma Therapies (2025)

gustav2025-10-27T23:00:57+01:00

Glioblastoma (GBM) remains the most aggressive and treatment-resistant primary brain tumor, with median overall survival rarely exceeding 15–20 months despite advances in surgery, imaging, and systemic therapy. The key barriers are persistent: incomplete resection, limited drug penetration across the blood–brain barrier (BBB), and a microenvironment that suppresses immune activity while promoting recurrence. In [...]

Beyond Incrementalism – Investing in the Next Blockbuster Glioblastoma Therapies (2025)gustav2025-10-27T23:00:57+01:00

Protokoll extra bolagsstämma 2025-09-12

gustav2025-09-15T21:52:54+02:00

Protokoll Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Protokoll extra bolagsstämma 2025-09-12gustav2025-09-15T21:52:54+02:00

Halvårsrapport 2025

gustav2025-08-26T00:48:38+02:00

Halvårsrapport 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Halvårsrapport 2025gustav2025-08-26T00:48:38+02:00

SI-053 treats glioblastomas regardless of tumour genotype

gustav2025-08-22T02:48:33+02:00

This document has been prepared by Double Bond Pharmaceutical for the purpose of summarising current scientific literature and providing a short assessment of the challenges and therapeutic opportunities in glioblastoma treatment. 13th August 2025. Glioblastomas' significant heterogeneity complicates diagnosis in an era of increasing reliance on genotyping, as traditional biopsies may provide an [...]

SI-053 treats glioblastomas regardless of tumour genotypegustav2025-08-22T02:48:33+02:00

Förslag till bolagsordning 2025-09-12

gustav2025-08-14T00:38:16+02:00

Förslag Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Förslag till bolagsordning 2025-09-12gustav2025-08-14T00:38:16+02:00

Kallelse till extra bolagsstämma 2025-09-12

gustav2025-08-14T00:36:44+02:00

Kallelse Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Kallelse till extra bolagsstämma 2025-09-12gustav2025-08-14T00:36:44+02:00

Anmälan till bolagsstämma 2025-09-12

gustav2025-08-14T00:34:42+02:00

Anmälan Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Anmälan till bolagsstämma 2025-09-12gustav2025-08-14T00:34:42+02:00

Årsstämma 2025

gustav2025-07-01T23:41:09+02:00

Årsstämma 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Årsstämma 2025gustav2025-07-01T23:41:09+02:00

Informationsdokument Bilaga IX

gustav2025-06-14T08:18:53+02:00

Disclaimer Viktig information På grund av legala restriktioner är informationen på den här delen av webbplatsen inte avsedd eller tillgänglig för vissa personer. Vi ber dig därför att ta del av följande information och lämna följande bekräftelse varje gång du önskar tillgång till här delen av webbplatsen. Vänligen notera att villkoren nedan kan [...]

Informationsdokument Bilaga IXgustav2025-06-14T08:18:53+02:00

Fullmaktsformulär till årsstämma 2025

gustav2025-05-23T10:13:53+02:00

Fullmakt Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]

Fullmaktsformulär till årsstämma 2025gustav2025-05-23T10:13:53+02:00

About gustav